Given the molecular heterogeneity of sarcomas as a group with a majority of tumors showing complex karyotypes and other entities being characterized by defined chromosomal translocations against the background of a largely stable genome it is intuitive that the biological (and clinical) role of YAP1/TAZ may well be very much different in various entities. The gene discussed is YAP1; the disease is sarcoma.